Epigenetics Diagnostics Market to Grow with a CAGR of 7.25% through 2028
Increasing incidence of complex diseases
and increasing pharmaceutical research and drug development are factors driving
the global Epigenetics Diagnostics market in the forecast period 2024-2028.
According to TechSci Research report, “Epigenetics
Diagnostics Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Epigenetics Diagnostics Market stood at USD 12.25 Billion
in 2022 and is anticipated to grow with a CAGR of 7.25% in the forecast period,
2024-2028. The field of epigenetics has rapidly evolved in recent years,
revolutionizing our understanding of gene regulation and its impact on health
and disease. Epigenetics diagnostics, a subfield within epigenetics research,
holds immense promise in revolutionizing healthcare by offering novel insights
into disease diagnosis, prognosis, and treatment response. The global
epigenetics diagnostics market is experiencing significant growth, and several
key factors are driving this expansion. One of the primary drivers behind the
growth of the global epigenetics diagnostics market is the escalating incidence
of complex diseases such as cancer, cardiovascular diseases, and neurological
disorders. Epigenetic modifications play a crucial role in the development and
progression of these diseases, making epigenetics diagnostics a valuable tool
for early detection and monitoring of disease progression.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Epigenetics
Diagnostics Market.”
The continuous advancements in
epigenetic research have led to the discovery of numerous epigenetic biomarkers
associated with various diseases. This has paved the way for the development of
innovative diagnostic tools that can detect specific epigenetic changes in DNA
or RNA, providing more accurate and reliable disease diagnosis and prognosis. The
era of personalized medicine is dawning, and epigenetics diagnostics are at its
forefront. These diagnostics enable healthcare providers to tailor treatments
based on an individual's unique epigenetic profile. This approach leads to more
effective therapies with fewer side effects, driving both patient outcomes and
the demand for epigenetics diagnostic tools.
The global population is aging, which is
contributing to an increase in age-related diseases such as cancer, Alzheimer's
disease, and osteoporosis. Epigenetics diagnostics can help in early disease
detection and monitoring, improving the quality of life for the elderly
population and reducing the burden on healthcare systems. Pharmaceutical
companies are increasingly incorporating epigenetics into their drug discovery
and development processes. Epigenetics diagnostics are vital in identifying
potential drug targets and predicting patient responses to novel therapies.
This integration of epigenetics into drug development pipelines is expected to
drive the growth of the epigenetics diagnostics market.
The Global Epigenetics Diagnostics Market is segmented
into product type, application, technology and company.
Based on technology, the DNA methylation segment has
emerged as the predominant market leader.
DNA
methylation technology has fueled groundbreaking research in the field of
epigenetics. It has allowed scientists to delve deep into the epigenetic
mechanisms underlying diseases and has paved the way for the development of
novel therapeutics.
Based on region, North America segment is expected to
grow during the forecast period. North America boasts a well-defined
regulatory framework that ensures the safety and effectiveness of diagnostic
tests. This regulatory clarity has fostered trust among healthcare
professionals and patients in epigenetics diagnostics. The region is home to several leading companies
specializing in epigenetics diagnostics, such as Illumina, Thermo Fisher
Scientific, and QIAGEN. These companies have played a significant role in
shaping the market and driving its growth.
The Asia Pacific region is experiencing rapid market
growth. The region’s leadership in the global epigenetics diagnostics market is
a testament to its commitment to advancing healthcare through innovative
technologies. The region's robust research and development ecosystem,
well-established healthcare infrastructure, and supportive regulatory framework
have all contributed to its dominant position.
Major companies operating in Global Epigenetics
Diagnostics Market are:
- Roche Diagnostics
- Thermo Fisher Scientific, Inc.
- Eisai Co. Ltd.
- Novartis AG
- Element Biosciences, Inc.
- Dovetail Genomics LLC.
- Illumina, Inc.
- ValiRx Plc.
- Abcam plc
Download
Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global epigenetics diagnostics market is poised
for remarkable growth, driven by factors such as the increasing incidence of
complex diseases, advancements in epigenetic research, personalized medicine,
the aging population, pharmaceutical research, technological advancements, and
rising awareness. With ongoing research and development efforts, strategic
collaborations, and regulatory support, the market for Epigenetics Diagnostics
is likely to continue its upward trajectory in the coming years, ultimately benefiting
patients and healthcare providers worldwide.,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Epigenetics Diagnostics Market By Product
(Reagents, Kits (Chip Sequencing Kit, Whole Genomic Amplification kit,
Bisulfite Conversion Kit, RNA Sequencing Kit, Others), Instruments, Enzymes,
Services), By Application (Oncology (Solid Tumors, Others),
Non-oncology(Inflammatory Diseases, Metabolic Diseases, Infectious Diseases, Cardiovascular
Diseases, Others)), By Technology (DNA Methylation, Histone Methylation,
Histone Acetylation, Large noncoding RNA, MicroRNA modification), By Region, By Competition Forecast &
Opportunities, 2018-2028F”, has evaluated the future growth potential of Global
Epigenetics Diagnostics Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Epigenetics
Diagnostics Market.
Contact
Mr. Ken Mathews
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com